174 related articles for article (PubMed ID: 20091528)
1. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
Smyth AR; Bhatt J
Cochrane Database Syst Rev; 2010 Jan; (1):CD002009. PubMed ID: 20091528
[TBL] [Abstract][Full Text] [Related]
2. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
Smyth AR; Bhatt J; Nevitt SJ
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD002009. PubMed ID: 28349527
[TBL] [Abstract][Full Text] [Related]
3. Macrolide antibiotics (including azithromycin) for cystic fibrosis.
Southern KW; Solis-Moya A; Kurz D; Smith S
Cochrane Database Syst Rev; 2024 Feb; 2(2):CD002203. PubMed ID: 38411248
[TBL] [Abstract][Full Text] [Related]
4. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
Smith S; Rowbotham NJ; Charbek E
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD008319. PubMed ID: 35914011
[TBL] [Abstract][Full Text] [Related]
5. Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis.
Lands LC; Stanojevic S
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD001505. PubMed ID: 31499593
[TBL] [Abstract][Full Text] [Related]
6. Inhaled corticosteroids for cystic fibrosis.
Balfour-Lynn IM; Welch K; Smith S
Cochrane Database Syst Rev; 2019 Jul; 7(7):CD001915. PubMed ID: 31271656
[TBL] [Abstract][Full Text] [Related]
7. Macrolide antibiotics for cystic fibrosis.
Southern KW; Barker PM; Solis-Moya A; Patel L
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD002203. PubMed ID: 23152214
[TBL] [Abstract][Full Text] [Related]
8. Sodium channel blockers for cystic fibrosis.
Burrows EF; Southern KW; Noone PG
Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD005087. PubMed ID: 24715704
[TBL] [Abstract][Full Text] [Related]
9. Nebuliser systems for drug delivery in cystic fibrosis.
Daniels T; Mills N; Whitaker P
Cochrane Database Syst Rev; 2013 Apr; (4):CD007639. PubMed ID: 23633344
[TBL] [Abstract][Full Text] [Related]
10. Nebuliser systems for drug delivery in cystic fibrosis.
Stanford G; Morrison L; Brown C
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD007639. PubMed ID: 37942828
[TBL] [Abstract][Full Text] [Related]
11. A comparison of aminoglycoside antibiotic serum concentrations collected by peripheral veins and peripherally inserted central catheters in adults with cystic fibrosis.
Sherwood SJ; Tak C; Bhakta ZN; Packer K; Jacobs H; Liou TG; Young DC
Pediatr Pulmonol; 2024 Jun; 59(6):1740-1746. PubMed ID: 38501330
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity.
Rybak MJ; Abate BJ; Kang SL; Ruffing MJ; Lerner SA; Drusano GL
Antimicrob Agents Chemother; 1999 Jul; 43(7):1549-55. PubMed ID: 10390201
[TBL] [Abstract][Full Text] [Related]
13. Aminoglycosides: single- or multiple-daily dosing? An updated qualitative systematic review of randomized trials on toxicity and efficacy.
Karimzadeh I; Abdollahpour-Alitappeh M; Ghaffari S; Mahi-Birjand M; Barkhordari A; Alemzadeh E
Curr Mol Med; 2023 Aug; ():. PubMed ID: 37533241
[TBL] [Abstract][Full Text] [Related]
14. Daily serum creatinine monitoring promotes earlier detection of acute kidney injury in children and adolescents with cystic fibrosis.
Downes KJ; Rao MB; Kahill L; Nguyen H; Clancy JP; Goldstein SL
J Cyst Fibros; 2014 Jul; 13(4):435-41. PubMed ID: 24718099
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis.
Dong M; Rodriguez AV; Blankenship CA; McPhail G; Vinks AA; Hunter LL
J Antimicrob Chemother; 2021 Oct; 76(11):2923-2931. PubMed ID: 34379758
[TBL] [Abstract][Full Text] [Related]
16. Systematic reviews and lifelong diseases.
Elphick HE; Tan A; Ashby D; Smyth RL
BMJ; 2002 Aug; 325(7360):381-4. PubMed ID: 12183313
[No Abstract] [Full Text] [Related]
17. Exploration of the relationship between cumulative exposure to tobramycin and ototoxicity in patients with cystic fibrosis.
Madaule J; Valenzuela F; Mittaine M; Gallois Y; Baladi B; Murris M; Calmels MN; Concordet D; Gandia P
J Cyst Fibros; 2023 Sep; 22(5):944-948. PubMed ID: 37088635
[TBL] [Abstract][Full Text] [Related]
18. Extended-interval aminoglycoside therapy for adult patients with febrile neutropenia: a systematic review.
Stabler SN; Ensom MH
Can J Hosp Pharm; 2011 May; 64(3):182-91. PubMed ID: 22479053
[TBL] [Abstract][Full Text] [Related]
19. Physiotherapy via telehealth for acute respiratory exacerbations in paediatric cystic fibrosis.
Benz C; Middleton A; Elliott A; Harvey A
J Telemed Telecare; 2023 Aug; 29(7):552-560. PubMed ID: 33726605
[TBL] [Abstract][Full Text] [Related]
20. Incidence and associated risk factors for systemic drug levels with inhaled aminoglycoside therapy.
Schultheis JM; Durham ME; Kram SJ; Kuhrt M; Gilstrap DL; Parish A; Green CL; Kram BL
J Antimicrob Chemother; 2023 Feb; 78(2):450-456. PubMed ID: 36512376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
